About this information
Search the summaries of completed Access to Information (ATI) requests to find information about ATI requests made to the Government of Canada after January 2020. If you find a summary of interest, you can request a copy of the records at no cost using the form below each summary. Requests made through this form are considered informal requests and are not subject to the same requirements as requests under the Access to Information Act (ATIA).
If you don’t find what you are looking for you can request additional government records under an institution’s control by contacting the institution’s Access to Information and Privacy Coordinator or by submitting a formal access to information request.
*All information provided will incorporate the necessary exemptions and exclusions as per the Access to Information Act and the Privacy Act.
Download datasets of the summaries of completed access to information requests.
Current Search
Report Type
Organization
Disposition
Year
Month
Found 5937 record(s)
Req # A-2023-001510
Adverse Drug Reaction (ADR) for DICLECTIN (doxylamine/pyridoxine). Report number: 001070859.Organization: Health Canada
June 2024
Req # A-2023-001511
Adverse Drug Reaction (ADR) for DICLECTIN (doxylamine/pyridoxine). Report number: 001070516.Organization: Health Canada
June 2024
Req # A-2023-001542
Adverse Drug Reactions (ADRs). Report numbers: E2B_06388027, 001051137, E2B_06450364, E2B_01526380, E2B_06515752.Organization: Health Canada
June 2024
Req # A-2023-001545
Adverse Drug Reactions (ADRs). Report numbers: E2B_06110117, E2B_06001457.Organization: Health Canada
June 2024
Req # A-2023-001557
Adverse Drug Reaction (ADR). Report number: 001073156.Organization: Health Canada
June 2024
Req # A-2023-001559
Adverse Drug Reactions (ADRs). Report numbers: E2B_06804716, E2B_06767690, E2B_06791052, E2B_06147523, E2B_06774403, E2B_06786042, 001071746, E2B_06815233, E2B_06818278, E2B_06805885.Organization: Health Canada
June 2024
Req # A-2023-001561
Adverse Drug Reaction (ADR). Report number: E2B_06694691.Organization: Health Canada
June 2024
Req # A-2023-001576
Briefing note in the Ministerial Executive Correspondence System (MECS) for the following file: 23-112026-78.Organization: Health Canada
June 2024
Req # A-2023-001582
Adverse Drug Reactions (ADRs) for Leuprorelin. Report numbers: E2B_06058779, E2B_06137873, E2B_06149226, E2B_06153462, E2B_06155423, E2B_06242847, E2B_06249825, E2B_06257614, E2B_06260684.Organization: Health Canada
June 2024
Req # A-2023-001584
Adverse Drug Reaction (ADR) for Bosentan. Report number: E2B_06842555.Organization: Health Canada
June 2024